Development of diagnostic nanotechnologies for precision medicine
Dr Wuethrich is an emerging research leader concurrently holding NHMRC Emerging Leadership and ARC DECRA. He completed his PhD at the University of Tasmania in 2016, after which he was awarded a Swiss National Science Foundation Fellowship to join the Centre for Personalised Nanomedicine to research electrohydrodynamic fluid flows for electrochemical biosensing. In 2018, Dr Wuethrich was awarded a UQ Development Fellowship to lead a research program on the development of diagnostic nanoplatforms for precision medicine with a particular focus on cancer biomarker detection in liquid biopsies.
Collaborations
Dr Wuethrich has established a network of national and international collaborators, working in partnership to explore the capabilities of our nanomaterial-based system to study cancer, infectious diseases, and immune overreactions. Collaborators include the Princess Alexandra Hospital, UQ Diamantina Institute, UQ Centre for Clinical Research, QIMR Berghofer, and the Dana-Farber Cancer Institute.
Funding
2022-2024 Cancer Australia (Priority-driven Collaborative Cancer Research Scheme): nanoIMPAC: Monitoring immune toxicities and tumour immune evasion in lung cancer
2021-2023 ARC Discovery Project: Single molecule sensing on nanopillars: Reading complex molecular circuits
2020-2024 NHMRC Investigator Grant: A protein phosphorylation mapping tool for monitoring tyrosine kinase inhibition therapy in cancer patients
2020 ARC DECRA awardee (DE200100345)
2020 Hunter Cancer Research Alliance grant
2019 University of Queensland Early Career Research Grant
2018-2020 UQ Development Fellowship
2016-2018 Swiss National Science Foundation Fellowship
Key Publications
1) Li, J.; Wuethrich, A*.; Sina, A. A. I.; Cheng, H.-H.; Wang, Y.; Behren, A.; Mainwaring, P. N.; Trau, M. A Digital Single-Molecule Nanopillar SERS Platform for Predicting and Monitoring Immune Toxicities in Immunotherapy. Nat. Commun. 2021, 12 (1), 1–12.
2) Wang, J.; Wuethrich, A.*; Sina, A. A. I.; Lane, R. E.; Lin, L. L.; Wang, Y.; Cebon, J.; Behren, A.; Trau, M. Tracking Extracellular Vesicle Phenotypic Changes Enables Treatment Monitoring in Melanoma. Sci. Adv. 2020, 6 (9), eaax3223.
3) Wang, J.; Kao, Y.; Zhou, Q.; Wuethrich*, A.; Stark, M. S.; Schaider, H.; Soyer, H. P.; Lin, L. L.; Trau, M. An Integrated Microfluidic-SERS Platform Enables Sensitive Phenotyping of Serum Extracellular Vesicles in Early Stage Melanomas. 2021, 2010296, 1–9. Advanced Functional Materials (2022), 32, 3, 2010296.
4) Zhang, Z.; Wang, J.; Shanmugasundaram, K. B.; Yeo, B.; Möller, A.; Wuethrich, A.*; Lin, L. L.; Trau, M. Tracking Drug-Induced Epithelial--Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay. Small 2020, 16 (13), 1905614.Small, 16 (2020), 1905614.
5) Khondakar, K. R.; Dey, S.; Wuethrich, A*.; Sina, A. A. I.; Trau, M. Toward Personalized Cancer Treatment: From Diagnostics to Therapy Monitoring in Miniaturized Electrohydrodynamic Systems. Acc. Chem. Res. 2019, 52 (8), 2113–2123.
(*co-first or co-corresponding author)